Dr.Mirjana kovac was trained as a Transfusion Medicine Specilaist at the University of Belgrade, Faculty of Medicine (1992-94). In the period of 1998-2000,she finished MSc studies, at the University of Belgrade, Faculty of Medicine. In the period of 2007- 2009.she finished my PhD studies at the University of Belgrade, Faculty of Medicine. In the later years,she was involved in the research of hemostasis disorders, particularly in domain of thrombosis development mechanism and all aspects of thrombotic processes associated with thrombophilia. Another important research activity involved the use of anticoagulant therapy in the treatment of thrombosis, especially the use of pharmacogenetic testing in the individualized antithrombotic therapy. Currently, she is involved in two research projects funded by the Ministry of Education, Science and Technological Development, Serbia. Besides, she is involved in the multicenter observational study on antithrombotic prevention in thrombophilia and pregnancy loss (OTTLIA study). As the Assistant Director, Education and Research Department,she is involved in all aspects of those two important activities of the Blood Transfusion Institute of Serbia.
Involved particularly in domain of thrombosis development mechanism and all aspects of thrombotic processes associated with thrombophilia. Another important research activity involves the use of anticoagulant therapy in the treatment of thrombosis, especially the use of pharmacogenetic testing in individualization of anticoagulant therapy
1. Mikovic D, Rakicevic L, Kovac M, Radojkovic D. Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost. 2000 ;84(4):723-4
2. AntonijeviÄ‡ N, StanojeviÄ‡ M, MiloseviÄ‡ R, MikoviÄ‡ D, Kovac M, TerziÄ‡ B, VasiljeviÄ‡ Z.Heparin-induced type II thrombocytopenia--new views on diagnosis and therapy.Med Pregl. 2003 May-Jun;56(5-6):247-50. Review. Serbian.
3. Djordjevic V, Rakicevic LJ, Mikovic D, Kovac M, Miljic P, Radojkovic D, Savic A Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. Acta Haematol. 2004;112(4):227-9.
4. AntonijeviÄ‡ N, StanojeviÄ‡ M, PeruniciÄ‡ J, DjokiÄ‡ M, MikoviÄ‡ D, Kovac M, MiljiÄ‡ P, MiloseviÄ‡ R, TerziÄ‡ B, VasiljeviÄ‡ Z. Thrombocytopenia induced by type II heparin and myocardial infarct: 2 case reports. Srp Arh Celok Lek. 2004 Jan-Feb;132(1-2):33-7. Serbian.
5. Antonijevic N, Stanojevic M, Milosevic R, Djordjevic V, Jaukovic M, Vukcevic V, Kovac M, Mikovic D, Radojkovic D, Vasiljevic Z.Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up. J Thromb Thrombolysis. 2005 ;19(2):93-5.
6. DordeviÄ‡ V, RakiÄ‡eviÄ‡ L, SpasiÄ‡ M, MikoviÄ‡ D, KovaÄ‡ M, RadojkoviÄ‡ D. Factor V Leiden, FII G20210A, MTHFR C677T mutations as risk factors for venous thrombosis during pregnancy and puerperium. Vojnosanit Pregl. 2005;62(3):201-5. Serbian.
7. Antonijevic NM, Savic NB, Perunicic J, Kovac M, Mikovic D, Stanojevic M, Calija B, Milosevic RA, Obradovic SD, Vasiljevic Z. Salvage late plasmapheresis in a patient with pulmonary embolism caused by heparin-induced thrombocytopenia primarily resistant to danaparoid sodium and lepirudin. J Clin Apher. 2006 ;21(4):252-5.
8. Kovac M, Mikovic D, Antonijevic N, Rakicevic L, Djordjevic V, Radojkovic D, Elezovic I. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population. J Thromb Thrombolysis. 2008;25(3):284-7.
9. Perunicic J, Antonijevic NM, Miljic P, Djordjevic V, Mikovic D, Kovac M, Djokic M, Mrdovic I, Nikolic A, Vasiljevic Z. Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome. J Thromb Thrombolysis. 2008 Oct;26(2):142-6.
10. Kovac M, RakiÄ‡eviÄ‡ L, MaslaÄ‡ A, RadojkoviÄ‡ D. The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use. Vojnosanit Pregl. 2009;66(8):617-21. Serbian.
11. DjuniÄ‡ I, Tomin D, AntonijeviÄ‡ N, Gradinac S, Kovac M, VidoviÄ‡ A, DjurasinoviÄ‡ V, ElezoviÄ‡ I. Heparin-induced thrombocytopenia occurring after surgical treatment of atrial myxoma-a case report. Srp Arh Celok Lek. 2009 Sep-Oct;137(9-10):540-4. Serbian.
12. Kovac M, Mitic G, Mikovic Z, Djordjevic V, Savic O, Mandic V, Rakicevic LJ, Antonijevic N, Radojkovic D. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancy-related venous thromboembolism. Gynecol Obstet Invest.
13. Kovac M, Mikovic Z, Rakicevic L, Srzentic S, Mandic V, Djordjevic V, Radojkovic D, Elezovic I. The use of D-dimer with new cutoff can be useful in diagnosis of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010 ;148(1):27-30.
14. Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis. 2010;21(6):558-63.
15. Kovac Z, Kovac M, Mitic G, Antonijevic N. The oncology treatment of patients who use oral anticoagulants is connected with high risk of bleeding complications. J Thromb Thrombolysis. 2010 ;30(2):210-4.